Landscapes / Targets
PI3Kα
30 drugs act on PI3Kα, in 70 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs30
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Kinase inhibitor |
Approved | 30 Nov 2026soonPhase 3 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 30 Nov 2026 · Phase 3 trial completes | ||||
| Also tested for | APDS, PIDs Linked to PI3K | ||||
| Open drug page | |||||
Kinase inhibitor |
Roche · Public ROG.SW |
Approved | 3 May 2027Phase 3 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | 3 May 2027 · Phase 3 trial completes | ||||
| Also tested for | Breast Cancer, Metastatic Breast Cancer and 12 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Approved | Jan 2028Phase 1/2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | Jan 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Breast Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer) and 5 more | ||||
| Open drug page | |||||
PI3K inhibitor |
Approved | Feb 2028Phase 3 trial completes | |||
| How it works | Blocks PI3K | ||||
| Next date | Feb 2028 · Phase 3 trial completes | ||||
| Also tested for | Lymphoma, Mycosis Fungoides and 1 more | ||||
| Open drug page | |||||
PI3K inhibitor |
Approved in China | — | |||
| How it works | Blocks PI3K | ||||
| Also tested for | Peripheral T Cell Lymphoma | ||||
| Open drug page | |||||
— |
Phase 3 | 26 Feb 2027Phase 1/2 trial completes | |||
| Next date | 26 Feb 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumors, Breast Cancer | ||||
| Open drug page | |||||
PI3K inhibitor |
Eli Lilly · Public LLY |
Phase 3 | Dec 2027Phase 2 trial completes | ||
| How it works | Blocks PI3K | ||||
| Next date | Dec 2027 · Phase 2 trial completes | ||||
| Also tested for | Breast Neoplasms, Breast Cancer and 3 more | ||||
| Open drug page | |||||
PI3K inhibitor |
Phase 3 | 30 Apr 2028Phase 3 trial completes | |||
| How it works | Blocks PI3K | ||||
| Next date | 30 Apr 2028 · Phase 3 trial completes | ||||
| Also tested for | PIK3CA Mutation, Breast Cancer and 14 more | ||||
| Open drug page | |||||
— |
Phase 3 | 30 Sep 2029Phase 3 trial completes | |||
| Next date | 30 Sep 2029 · Phase 3 trial completes | ||||
| Also tested for | Solid Tumor, Gastric Type Adenocarcinoma (GAS) With STK11 Mutation and 1 more | ||||
| Open drug page | |||||
— |
Phase 2 | 30 Dec 2026Phase 2 trial completes | |||
| Next date | 30 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Ischemic Stroke, Tandem Occlusion | ||||
| Open drug page | |||||
PI3K inhibitor |
Phase 2 | 31 Dec 2026Phase 2 trial completes | |||
| How it works | Blocks PI3K | ||||
| Next date | 31 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Triple Negative Breast Cancer (TNBC) | ||||
| Open drug page | |||||
PI3K inhibitor |
Phase 2 | Jan 2027Phase 1/2 trial completes | |||
| How it works | Blocks PI3K | ||||
| Next date | Jan 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Uveal Melanoma, Solid Tumor, Adult and 7 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | Feb 2027Phase 1/2 trial completes | |||
| Next date | Feb 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Focal Cortical Dysplasia, Tuberous Sclerosis Complex (TSC) and 1 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | Apr 2027Phase 1/2 trial completes | |||
| Next date | Apr 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumors | ||||
| Open drug page | |||||
— |
Phase 1/2 | 30 Jun 2027Phase 1/2 trial completes | |||
| Next date | 30 Jun 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumors, Advanced Breast Cancer | ||||
| Open drug page | |||||
— |
Phase 2 | Sep 2027Phase 2 trial completes | |||
| Next date | Sep 2027 · Phase 2 trial completes | ||||
| Also tested for | Peripheral T Cell Lymphoma | ||||
| Open drug page | |||||
— |
Phase 2 | 9 Jan 2028Phase 2 trial completes | |||
| Next date | 9 Jan 2028 · Phase 2 trial completes | ||||
| Also tested for | Advanced Solid Tumors, Locally Advanced or Metastatic Solid Tumors and 1 more | ||||
| Open drug page | |||||
PI3K inhibitor |
Kyowa Kirin +1 |
Phase 2 | 31 May 2028Phase 2 trial completes | ||
| How it works | Blocks PI3K | ||||
| Next date | 31 May 2028 · Phase 2 trial completes | ||||
| Also tested for | Indolent B-cell Non-Hodgkin's Lymphoma | ||||
| Open drug page | |||||
PI3K inhibitor |
Phase 2 | Sep 2028Phase 2 trial completes | |||
| How it works | Blocks PI3K | ||||
| Next date | Sep 2028 · Phase 2 trial completes | ||||
| Also tested for | Endometrial Cancer, HR+ HER2- Breast Cancer | ||||
| Open drug page | |||||
— |
Phase 2 | 31 Dec 2029Phase 1/2 trial completes | |||
| Next date | 31 Dec 2029 · Phase 1/2 trial completes | ||||
| Also tested for | Ovarian Cancer, Recurrent Cancer and 2 more | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 29 of 30 drugs. The other 1 is marked “not checked” in the list. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026